Breakthrough polymer-based therapy shows promise in reversing Huntington’s disease symptoms by preventing toxic protein clumps and enhancing neuronal survival.
Q3’24 Survey: What are Psychedelics Investors Excited About? – Psychedelic Alpha
Earlier, we shared the high-level results of our Q3’24 Psychedelic Investor Survey, our third such survey. Here, we take a closer look at investors’ qualitative responses
November 25, 2024